Observation Of Hospital Homemade Paishi Decoction Series Applied In Perioperation Of Ureterscope Lithotripsy

PURPOSE:Ureterscope lithotripsy (URL) is mainly used minimally invasive therapy for middle/lower ureteral calculi. But complications such as residual stone, pain, infection, haematuria, decline of renal function cause trouble to both doctor and patient. Ways to solve these problems is always what urology surgeons are searching for. Traditional Chinese medicine has special effect of removing and litholysis, which is able to reduce calculi inflammation adhesion, cause elimination of calculi, improve renal function and quality of patients’life in conjunction with URL.Purpose:searching for optimized therapy of integrated traditional Chinese and western medicine through observation of Paishi decoction series (Paishi decoction II, III) made by our institute on their clinical effect and safety.Method:choose179patients who took URSL for middle/lower ureteral calculi during Dec.2009Jan.2012, and divide them into two groups:Paishi decoction in conjunction with URSL (90) and URSL (89).Therapy group:eating Paishi decoction III from7days before URSL.1potion for a day,2-3times, oral; replace it with Paishi decoction II2-3days after surgery,1potion for a day,2-3times. Last for8weeks.Contrast group:normal URSL without any Paishi decoction before or after surgery. Two groups of intraoperative are placed F4.7/F6conventional bud brand double J tube, go after two week cystoscope pull out.Reference to urological diseases, diagnosis and treatment Guide (2009edition of People’s Health Publishing House) and "Chinese drug clinical research indicators Principles relevant standards, after two weeks, four weeks, eight weeks to observe the two sets of residual stone rate, clinical symptomsrating changes, changes of renal function (serum creatinine), and security indicators (blood, urine, liver function, electrocardiogram).Result:1. Postoperative residual stone rate:the treatment group after2weeks,4weeks,8weeks of residual stone rate were5.52%,4.24%,2.10%; control group after2weeks,4weeks,8weeks of residual stone rate were10.21%,8.42%,4.56%two groups compared to the significant difference (P<0.05), residual stone rate of treatment group was significantly lower than the control group.2.Clinical score:the treatment group after2weeks4weeks8weeks10±2.23,6±2.02,1±1.13. Control group after2weeks,4weeks,8weeks, respectively, compared to12±2.21,8±2.18,3±1.34two groups a significant difference (P<0.05) in improving clinical symptoms of the patients, treatment group than the control group.3. Renal function (serum creatinine):treatment group after2weeks,4weeks,8weeks, respectively132±10.21,103±9.27,80± 7.34. Compared to the control group after2weeks,4weeks,8weeks, respectively177±11.23,124±10.31,100±8.34two groups have significant difference (P<0.05) in improving renal function in patients, the treatment group than the control group.4.Security:before and after treatment, patients treated with blood, stool, liver and kidney function, ECG showed no obvious abnormal clinical significance of changes.Conclusion:Our research of the row II number, III stone soup, and URSL both combined application, can effectively reduce the postoperative residual stone rate and improve the cl inical symptoms and renal function, improve the quality of life of the patients, good safety; Have good clinical application and dissemination value.